• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vertex Pharmaceuticals (NQ:VRTX)

    422.60 +1.21 (+0.29%)
    Streaming Delayed Price Updated: 12:51 PM EDT, Oct 27, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Vertex Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    60 61 Next >
    Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030
    Vertex appears to be by far the better buy right now. 
    Via The Motley Fool
    Topics Intellectual Property
    The Best Stocks to Invest $50,000 In Right Now
    There's no guarantee that any stock will deliver positive returns. But the odds look good for these three. 
    Via The Motley Fool
    Topics Artificial Intelligence Energy
    Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Value Investment Case Study
    Vertex Pharmaceuticals (VRTX) presents a value investing case with strong profitability, a debt-free balance sheet, and a valuation that appears attractive relative to its industry peers. 
    Via Chartmill
    2 Growth Stocks to Invest $1,000 in Right Now
    These companies have a habit of beating the market, and they are far from having peaked. 
    Via The Motley Fool
    Topics Artificial Intelligence World Trade
    2 Soaring Cathie Wood Stocks to Buy and Hold
    These companies' market-beating fuel hasn't run out yet. 
    Via The Motley Fool
    Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market
    Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment. 
    Via Benzinga
    Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Offers Affordable Growth in Biotech
    Vertex Pharmaceuticals (VRTX) offers strong growth, solid earnings, and a robust financial position, all at a reasonable price compared to biotech peers. 
    Via Chartmill
    2 Unstoppable Growth Stocks to Buy During a Market Crash
    Here are two smart ways to prepare for the next market downturn. 
    Via The Motley Fool
    Topics Government Stocks World Trade
    Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
     
    Via Benzinga
    4 Healthcare Stocks to Buy Now
    As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
     
    Via Benzinga
    The Smartest Growth Stock to Buy With $500 Right Now
    Vertex isn't your run-of-the-mill biotech stock. 
    Via The Motley Fool
    Topics Economy
    Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?
    Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital, which is disappointing considering the S&P 500 has climbed by 34.7%. This... 
    Via StockStory
    Topics Stocks
    Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500
    Tariffs aren't likely to weigh on growth at these companies. 
    Via The Motley Fool
    Topics Government Stocks World Trade
    Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
     
    Via Benzinga
    1 Healthcare Stock with Exciting Potential and 2 Facing Challenges
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
    Via StockStory
    Topics Stocks
    2 Beaten-Down Stocks Primed for a Comeback
    The market is sleeping on these stocks, but you don't have to. 
    Via The Motley Fool
    Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
    As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
    Via MarketMinute
    Topics Artificial Intelligence Climate Change Economy
    ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'
    Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&P Small-Cap ETF. Jim Lebenthal recommends Vertex Pharmaceuticals (VRTX). 
    Via Benzinga
    Topics ETFs Stocks
    Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday
     
    Via Benzinga
    Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
    London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
    Via TokenRing AI
    Topics Artificial Intelligence
    Healthcare Sector Defies Headwinds, Rallies on Wall Street Amidst Shutdown and Jobs Data
    New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    10 Health Care Stocks Whale Activity In Today's Session
     
    Via Benzinga
    What Does the Market Think About Vertex Pharmaceuticals Inc?
     
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga
    2 S&P 500 Stocks to Research Further and 1 We Avoid
    The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
    Via StockStory
    Topics Stocks
    5 Top Stocks to Buy in October
    These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term. 
    Via The Motley Fool
    Topics Stocks
    Pharma Tariffs Back In Spotlight On New Trump Threat
    President Donald Trump threatened 100% tariffs on some drug imports. 
    Via Investor's Business Daily
    Topics ETFs Government World Trade
    Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
    Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
    Via Benzinga
    Topics Government World Trade
    CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    60 61 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.